CTMX Stock Analysis: Buy, Sell, or Hold?
CTMX - CytomX Therapeutics, Inc.
$3.82
0.22 (6.11%)
▲
5d:
+16.82%
30d:
+20.89%
90d:
-16.23%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.1/10
Get Alerted When CTMX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CTMX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CTMX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CTMX is currently trading at $3.82, which is considered extended relative to its 30-day fair value range of $2.97 to $3.60.
Technical Outlook: Technically, CTMX is in a strong downtrend. The price is approaching resistance at $3.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.1% recently.
Market Sentiment: CTMX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.50 (+227.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTMX is in a strong downtrend. The price is approaching resistance at $3.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.1% recently.
Market Sentiment: CTMX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.50 (+227.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.97 -
$3.60
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+6.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.1%)
- BULLISH: Trading 227.2% below Wall St target ($12.50)
Trading Range Analysis
30-Day Trading Range
$2.97 -
$3.60
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.89
Resistance Level
$3.90
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.86
Wall Street Target
$12.50
(+227.2%)
Revenue Growth (YoY)
-79.9%
Earnings Growth (YoY)
60.6%
Profit Margin
-166.4%
Share & Embed Analysis
Last updated: July 02, 2026 10:34 PM ET
Data refreshes hourly during market hours. Next update: 11:34 PM
Data refreshes hourly during market hours. Next update: 11:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTMX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Ogden
SELL
19323 shares
2026-03-17
Marcia Belvin
SELL
31492 shares
2026-03-17
Sean A Mccarthy
SELL
118969 shares
2026-03-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
